Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  peginterferon alfa-2b
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Peginterferon Alfa-2b in Treating Younger Patients with Neurofibromatosis Type 1-Related Symptomatic or Life-Threatening Plexiform Neurofibromas That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 months to 21 years
Trial IDs: Peg-Intron, NCI-2014-02593, NCI-2013-01444, NCT00678951, Peg Interferon, UPCI 06-116, NCT00396019
Peginterferon alfa-2b in Treating Younger Patients with Craniopharyngioma That is Recurrent or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 25 years
Trial IDs: PBTC-039, NCI-2013-01639, NCT01964300
Pegylated Interferon Alpha-2b and Capecitabine in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC 17759, NCI-2014-01864, 14.06.0011, NCT02218164
Pembrolizumab and Peginterferon Alfa-2b in Treating Patients with Advanced Melanoma That Cannot Be Removed By Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-105, NCI-2014-01354, MK-3475, UPCI 13-105, NCT02112032
An Observational Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon A Versus Sylatron
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: Merck MISP 50422, NCI-2015-01266, NCT01986712
Start Over